Armis Biopharma® focuses on developing antimicrobial and anti-toxin products. Its technology includes a proprietary antimicrobial agent, Veriox®, that claims to eliminate various pathogens and chemical/biological threats.

Armis Biopharma®

Armis Biopharma | 45 followers on LinkedIn. Improving Societal Health by Protecting Humans, Animals, and the Environment from Harmful and Resistant Pathogens

Global Medical Device Executive ⇨ Strategic Direction, Vision & Execution for Transformative Product Innovation & Commercialization

Michael Voss

Operations Director - Product Development at Armis Biopharma

Jamie Reese

Manager at Armis Biopharma

Angela DeVary

Armis Biopharma

Another opportunity on Thursday to share the Armis Biopharma to investment opportunity.

May 31, 2023 - Armis Biopharma Announces 510(k) Clearance for VeriCyn® Wound Wash #pressrelease #VeriCynWoundWash #ArmisBiopharma

Our very own, Randy Hubbell will be presenting the Armis Biopharma opportunity at LSI on Thursday, March 21 at 8:45am PT (track 3). Also, you can visit both Randy Hubbell and Michael Voss at the Innovators Pavilion all week. #infectioncontrol #oralhygiene #decontamination #ArmisBiopharma #ArmisBiopharmaDental #LSI2024 #LSIalumni

On September 28, 2023 Armis Biopharma Announces Receipt of a $20.3 Million Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds #Future #ArmisBiopharma #verioxdecon #dtra #defensethreatreductionagency #warfighter

Armis Biopharma Announces the Addition of Two Key Executives to Enhance Commercialization of their Product Portfolio. @RandyHubbell @MikeVoss @TedZiemann #Future #ArmisBiopharma #HumanResources #businessintelligence #Management

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 8:46 AM	e429b074
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 8:46 AM	56c978f0
crunchbase trigger	general	Nov 27, 2024 12:50 PM	00257a99
crunchbase profile	general
li profile	general	Nov 12, 2024 8:46 AM	6b64d618
translate crunchbase fundingrounds	general
peers	general	Nov 12, 2024 8:46 AM	c18a01da
news basic	general	Nov 12, 2024 8:46 AM	d9b45c20
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ARMI

COM:ARMISBIOPHARMA

Armis Biopharma®